Case Report


Temozolomide regulates primary central nerve system lymphoma, being resistant to high dose methotrexate-based chemotherapy and radiation

1 MD, Director, Department of Neurosurgery, Hokuto Hospital, Obihiro, Hokkaido, Japan

Address correspondence to:

Akira Tempaku

7-5, Inada-cho-kisen, Obihiro, Hokkaido 080-0833,

Japan

Message to Corresponding Author


Article ID: 100140Z10AT2025

doi: 10.5348/100140Z10AT2025CR

Access full text article on other devices

Access PDF of article on other devices

How to cite this article

Tempaku A. Temozolomide regulates primary central nerve system lymphoma, being resistant to high dose methotrexate-based chemotherapy and radiation. J Case Rep Images Oncology 2025;11(1):1–4.

ABSTRACT


Introduction: Primary central nerve system lymphoma (PCNSL) is an intracranial malignancy. Combined chemotherapy with methotrexate, procarbazine, vincristine, and Rituximab, following radiation, sometimes results in partial response or progressive disease. Temozolomide (TMZ) administration has been proposed to salvage therapy.

Case Report: A 72-year-old man had headache and forgetfulness. Mild disorientation was observed. Head magnetic resonance image revealed a mass lesion in the right frontal lobe. Pathological examination after an incisional biopsy revealed a diagnosis of diffuse large B cell lymphoma. Standard treatment consisted of 6 cycles of high-dose methotrexate-based chemotherapy with procarbazine and vincristine. Three cycles of high-dose methotrexate-based chemotherapy with procarbazine and vincristine, combined with Rituximab. Further, focal radiation therapy against core lesion with marginal area irradiation was performed. In spite of total standard treatment, the lesion was not under regulation. The patient continued TMZ therapy 29 cycles on an outpatient basis due to psychiatric complications that made it difficult to continue intravenous treatment in the hospital. The tumor mass and surrounding edematous lesions decreased.

Conclusion: Oral TMZ administration was effective in an elderly patient with PCNSL, who had failed standard chemotherapy and radiation therapy. It was less invasive, allowed for transition to outpatient management, and provided adequate therapeutic benefit. Future indications for similar cases should be considered.

Keywords: Methotrexate, Primary central nerve system lymphoma, Salvage therapy, Temozolomide

SUPPORTING INFORMATION


Author Contributions

Akira Tempaku - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Guaranter of Submission

The corresponding author is the guarantor of submission.

Source of Support

None

Consent Statement

Written informed consent was obtained from the patient for publication of this article.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Conflict of Interest

Author declares no conflict of interest.

Copyright

© 2025 Akira Tempaku. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.